IBDEI1RA ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,29402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29402,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,29402,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,29402,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,29403,0)
 ;;=L56.3^^135^1361^268
 ;;^UTILITY(U,$J,358.3,29403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29403,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,29403,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,29403,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,29404,0)
 ;;=L57.0^^135^1361^12
 ;;^UTILITY(U,$J,358.3,29404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29404,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,29404,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,29404,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,29405,0)
 ;;=L60.0^^135^1361^161
 ;;^UTILITY(U,$J,358.3,29405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29405,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,29405,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,29405,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,29406,0)
 ;;=L60.1^^135^1361^234
 ;;^UTILITY(U,$J,358.3,29406,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29406,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,29406,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,29406,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,29407,0)
 ;;=L60.2^^135^1361^233
 ;;^UTILITY(U,$J,358.3,29407,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29407,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,29407,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,29407,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,29408,0)
 ;;=L60.3^^135^1361^170
 ;;^UTILITY(U,$J,358.3,29408,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29408,1,3,0)
 ;;=3^Nail Dystrophy
 ;;^UTILITY(U,$J,358.3,29408,1,4,0)
 ;;=4^L60.3
 ;;^UTILITY(U,$J,358.3,29408,2)
 ;;=^5009236
 ;;^UTILITY(U,$J,358.3,29409,0)
 ;;=L60.4^^135^1361^88
 ;;^UTILITY(U,$J,358.3,29409,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29409,1,3,0)
 ;;=3^Beau's Lines
 ;;^UTILITY(U,$J,358.3,29409,1,4,0)
 ;;=4^L60.4
 ;;^UTILITY(U,$J,358.3,29409,2)
 ;;=^5009237
 ;;^UTILITY(U,$J,358.3,29410,0)
 ;;=L60.5^^135^1361^290
 ;;^UTILITY(U,$J,358.3,29410,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29410,1,3,0)
 ;;=3^Yellow Nail Syndrome
 ;;^UTILITY(U,$J,358.3,29410,1,4,0)
 ;;=4^L60.5
 ;;^UTILITY(U,$J,358.3,29410,2)
 ;;=^5009238
 ;;^UTILITY(U,$J,358.3,29411,0)
 ;;=L60.8^^135^1361^168
 ;;^UTILITY(U,$J,358.3,29411,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29411,1,3,0)
 ;;=3^Nail Disorders NEC
 ;;^UTILITY(U,$J,358.3,29411,1,4,0)
 ;;=4^L60.8
 ;;^UTILITY(U,$J,358.3,29411,2)
 ;;=^5009239
 ;;^UTILITY(U,$J,358.3,29412,0)
 ;;=L62.^^135^1361^169
 ;;^UTILITY(U,$J,358.3,29412,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29412,1,3,0)
 ;;=3^Nail Disorders in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,29412,1,4,0)
 ;;=4^L62.
 ;;^UTILITY(U,$J,358.3,29412,2)
 ;;=^5009241
 ;;^UTILITY(U,$J,358.3,29413,0)
 ;;=L64.9^^135^1361^33
 ;;^UTILITY(U,$J,358.3,29413,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29413,1,3,0)
 ;;=3^Androgenic Alopecia,Unspec
 ;;^UTILITY(U,$J,358.3,29413,1,4,0)
 ;;=4^L64.9
 ;;^UTILITY(U,$J,358.3,29413,2)
 ;;=^5009249
 ;;^UTILITY(U,$J,358.3,29414,0)
 ;;=L65.9^^135^1361^231
 ;;^UTILITY(U,$J,358.3,29414,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29414,1,3,0)
 ;;=3^Nonscarring Hair Loss,Unspec
 ;;^UTILITY(U,$J,358.3,29414,1,4,0)
 ;;=4^L65.9
 ;;^UTILITY(U,$J,358.3,29414,2)
 ;;=^5009252
 ;;^UTILITY(U,$J,358.3,29415,0)
 ;;=L70.0^^135^1361^6
 ;;^UTILITY(U,$J,358.3,29415,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,29415,1,3,0)
 ;;=3^Acne Vulgaris
 ;;^UTILITY(U,$J,358.3,29415,1,4,0)
 ;;=4^L70.0
